COVID vaccine weekly: reopening will test the strength of England’s immunity

COVID vaccine weekly: reopening will test the strength of England's immunity

England has now lifted nearly all of its coronavirus restrictions. Cases are high and rising, but the country’s vaccine coverage is among the best the world, meaning that the power of vaccines to control the virus will now be firmly put to the test. How will this battle play out?

Possibly not very well, argues Zania Stamataki, senior lecturer in viral immunology at the University of Birmingham. Vaccines are effective at reducing transmission and disease, but they don’t completely prevent either among the vaccinated. Removing other control measures will definitely see infections, hospitalisations and deaths increase.

Read more:
July 19: Three experts share their thoughts on the end of COVID restrictions in England

We also don’t yet know the duration of vaccine-induced protection – and there’s some new research that suggests that antibody levels may drop off over time, which could allow for greater transmission and illness in the future. On top of this, removing restrictions and letting infections spiral raises the risk of new variants emerging that might be able to spread more easily or evade immunity.

The delta variant is a sign of what can happen when the virus is given the opportunity to mutate. As well as being more transmissible, there’s growing evidence that delta has evolved some ability to escape the effects of vaccines too – as Zania explains separately here. New research shows that in people who’ve only had a single vaccine dose, delta is less sensitive to the effects of antibodies.

Read more:
COVID: study finds lower antibody activity against delta variant at single dose – but vaccines still work

This is our weekly round-up of expert information about the COVID-19 vaccines.
The Conversation, a not-for-profit group, works with a wide range of academics across its global network to produce evidence-based analysis and insights. Get more regular updates from trusted experts by subscribing to our free newsletter .

And the fact that we’re already seeing relatively high numbers of infections among the double vaccinated is a warning that we’ve still got plenty of new cases ahead of us. This isn’t a sign that the vaccines aren’t working, argues Jamie Hartmann-Boyce of the Centre for Evidence-Based Medicine at the University of Oxford, but a confirmation of what we already know: that they aren’t 100% effective. With lots of virus circulating and the majority of UK adults double jabbed, a sizeable number of cases among those fully vaccinated is to be expected.

Read more:
COVID: the reason cases are rising among the double vaccinated – it’s not because vaccines aren’t working

Pleasingly though, there’s some early evidence that symptoms are less severe in those who’ve had both doses. Vaccinated COVID-19 patients report the same types of symptoms as unvaccinated ones, but have fewer of them. Their symptoms also last for a shorter amount of time.

A syringe filled with flu vaccine
Drawing comparisons with the flu vaccine could be a good way to drive COVID-19 vaccine uptake.
Michele Ursi/Shutterstock

Finally, the rising number of cases among the vaccinated shouldn’t distract from the fact that there’s still a notable portion of British adults – 12% – who haven’t had a single vaccine dose. One way of convincing this group to come forward and take one could be to underline how much more effective COVID-19 vaccine are than jabs for many other diseases, suggest Colin Davis and Ryan McKay.

In a newly published piece of research, they show how contrasting the effectiveness of COVID-19 vaccines with those for seasonal flu, which on average are far less protective, makes people regard coronavirus vaccines much more favourably. And importantly, this happens without perceptions of flu vaccines taking a hit.

Read more:
Vaccines for COVID are much more effective than for flu – and reminding people could drive down hesitancy

Get the latest news and advice on COVID-19, direct from the experts in your inbox. Join hundreds of thousands who trust experts by subscribing to our newsletter.

The Conversation